David Harlan, M.D.

David is the William and Doris Krupp Professor of Medicine and Chief of the Diabetes Division at the University of Massachusetts School of Medicine, where he also serves as Co-Director of the Diabetes Center of Excellence.  From 2007 to 2010, he served as head of the Diabetes, Endocrinology, & Metabolic Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). From 1999 to 2007, he was head of the Transplantation and Autoimmunity Branch at the NIH. His research interests are autoimmune illness – especially insulin-dependent diabetes mellitus – and tolerance mechanisms in organ and tissue transplantation. David has received numerous honors and awards, including the U.S. Navy Legion of Merit and the U.S. Public Health Service Physician Researcher of the Year Award. He has held academic medical appointments at UCSD, Duke University, and Uniformed Services University of Health Sciences. David earned his B.S. from the University of Michigan and his M.D. from Duke University. He continued his postgraduate training at Duke, where he was an intern, resident, and fellow in endocrinology.


Marc Hellerstein, M.D., Ph.D.

Marc is a Professor of Medicine and occupies an endowed chair at University of California Berkeley and maintains a joint appointment in the Department of Medicine at UC San Francisco. Dr. Hellerstein completed medical training at Yale Medical School with a fellowship in endocrinology at New England Medical Center and a Ph.D. in nutritional biochemistry from Massachusetts Institute of Technology.  Dr. Hellerstein’s major research interest has been the measurement in vivo of metabolic fluxes through pathways critical to health and disease as biomarkers for drug development and clinical diagnostics. This research has resulted in more than 250 publications, 70 issued patents, 40 pharmaceutical research programs and participation on several editorial boards, including Science Translational Medicine.  In 2001, Dr. Hellerstein co-founded a biotech company, KineMed, Inc., that serves major pharmaceutical clients by making predictions of efficacy and toxicity to accelerate and reduce the cost of drug development.  He currently serves as chairman of the KineMed, Inc. Scientific Advisory Board.


Ronald Krauss, M.D.

Ronald is a Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, Adjunct Professor in the Department of Medicine at University of California, San Francisco and in the Department of Nutritional Sciences at Unversity of California, Berkeley, and Guest Senior Scientist in the Department of Genome Sciences of Lawrence Berkeley National Laboratory. He then joined the staff of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, first as Clinical Associate and then as Senior Investigator in the Molecular Disease Branch.  He has published over 400 research articles and reviews on genetic, dietary, and drug effects on plasma lipoproteins and coronary artery disease. In recent years Dr. Krauss’ work has focused on interactions of genes with dietary and drug treatments that affect metabolic phenotypes and cardiovascular disease risk.

Dr. Krauss is board-certified in internal medicine, endocrinology and metabolism, and is a member of the American Society for Clinical Investigation, a Fellow of the American Society of Nutrition and the American Heart Association (AHA), and a Distinguished Fellow of the International Atherosclerosis Society. He has served on the U.S. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults,  was the founding chair of the AHA Council on Nutrition, Physical Activity, and Metabolism, and is a National Spokesperson for the AHA. Dr. Krauss has also served on both the Committee on Dietary Recommended Intakes for Macronutrients and the Committee on Biomarkers of Chronic Disease of the Institute of Medicine of the National Academy of Sciences.

He received his undergraduate and medical degrees from Harvard University with honors and served his internship and residency on the Harvard Medical Service of Boston City Hospital. 


Kevin Schulman, M.D.

Kevin is a professor of Medicine and Business Administration at Duke University, where he also serves as the director of the Center for Clinical and Genetic Economics and as an associate director of the Duke Clinical Research Institute. His research interests include health services research and policy; health economics and economic evaluation in clinical research; and medical decision making, especially in patients with life-threatening conditions.  Kevin’s other university affiliations include the Trent Center for Bioethics, Humanities and History of Medicine; the Duke Translational Research Institute Pilot Project Advisory Committee; and the Duke Global Health Institute; and the advisory board for the Centre for Healthcare Policy and Management at the China Europe International Business School (CEIBS). He has published more than 350 papers and book chapters, and is a fellow of the American College of Physicians and an elected member of the American Society for Clinical Investigation.  He received his M.D. from the New York University School of Medicine and his M.B.A. from the University of Pennsylvania Wharton School. He completed a residency in internal medicine at the University of Pennsylvania.


Allan Sniderman, M.D.

Allan is the Edwards Professor of Cardiology and Professor of Medicine at McGill University, and Director of the Mike Rosenbloom Laboratory for Cardiovascular Research at Royal Victoria Hospital in Montreal. His current research interests are to understand the regulation of plasma LDL, to create simplified but advanced diagnostic algorithms to recognize and treat those with and those at high risk of vascular disease, and to develop new models to determine the absolute value of different strategies to identify and treat those at risk of vascular disease.  He began and has continued a series of studies, which identified the most common dyslipoproteinemia associated with coronary artery disease – hyperTg hyperapoB.  Study of the pathophysiology of hyperTg hyperapB led to studies of the regulation of hepatic apoB secretion and the uptake and release of fatty acids by adipose tissue. Allan has conducted an extensive series of epidemiological studies, which have demonstrated apoB to be superior to LDL-cholesterol as a marker of the risk of vascular disease.  He obtained his M.D. from the University of Toronto, did his clinical training at McGill University, and studied lipoprotein metabolism at the University of California at San Diego.


  • Donate or get involved Connect and talk to us